News
Novo Nordisk, Zepbound
Digest more
Allison Stange lost 40 pounds since starting Zepbound in April 2024, improving both her blood pressure and sleep apnea. Now ...
CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...
Eli Lilly and Company's stock dropped 11% after CVS's Zepbound exclusion, but analysts see a mispricing opportunity. Click ...
MedPage Today on MSN1d
CVS Drops Obesity Drug; Once-Weekly Growth Hormone; WeightWatchers' BankruptcyPeople prescribed GLP-1 agents liraglutide (Saxenda) or semaglutide for weight loss decreased their alcohol intake by almost ...
Zacks.com on MSN12h
Lilly Down 17% Since Q1 Results: Should You Buy the Dip in LLY Stock?Despite its expensive valuation and declining estimates, we suggest investors hold LLY stock as the company boasts solid ...
Starting July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial template ...
The deal could expand access to its in-demand obesity drug at the expense of Eli Lilly, whose shares fell by double digits on ...
Eli Lilly shares dropped Thursday as Novo Nordisk notched a coverage win for its obesity drug, a sign of the competition in ...
CVS reported first quarter earnings Thursday, blowing past Wall Street's expectations and ending anxiety over Medicare ...
Effective July 1, 2025, CVS Caremark will place Wegovy injection 2.4 mg as preferred on its commercial template formularies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback